Evolus, Inc.
Evolus, Inc. (EOLS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
eols · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Evolus, Inc. (EOLS) measures how much investors pay for each dollar of the company's trailing earnings. EOLS's current PE ratio of N/A is calculated by dividing its stock price of $6.68 by its TTM earnings per share of -$0.67.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2015 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Evolus, Inc.You EOLS | $440M | N/A | — | -$0.67 |
 Autolus Therapeutics plc AUTL | $387M | N/A | — | -$1.08 |
 CeriBell, Inc. CBLL | $689M | N/A | — | -$1.46 |
 Enhabit, Inc. EHAB | $707M | N/A | — | -$0.09 |
 OrthoPediatrics Corp. KIDS | $468M | N/A | — | -$1.69 |
 Kamada Ltd. KMDA | $418M | 20.15x | — | $0.35 |
 Neurogene Inc. NGNE | $452M | N/A | — | -$4.27 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.80 | — | |
2024-12-31 FY2024 | — | $-0.81 | — | |
2023-12-31 FY2023 | — | $-1.08 | — | |
2022-12-31 FY2022 | — | $-1.33 | — | |
2021-12-31 FY2021 | — | $-0.94 | — | |
2020-12-31 FY2020 | — | $-4.83 | — | |
2019-12-31 FY2019 | — | $-3.19 | — | |
2018-12-31 FY2018 | — | $-1.92 | — | |
2017-12-31 FY2017 | — | $-0.19 | — | |
2016-12-31 FY2016 | — | $-1.08 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Evolus, Inc. (EOLS) measures how much investors pay for each dollar of the company's trailing earnings. EOLS's current PE ratio of N/A is calculated by dividing its stock price of $6.68 by its TTM earnings per share of -$0.67.
Frequently asked questions
EOLS pe ratio · 6 questionsEOLS's current PE ratio is N/A as of 2026-06-08, based on a stock price of $6.68 and TTM EPS of -$0.67. Data sourced from Financial Modeling Prep via EOLS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Evolus, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08